Please login to the form below

Not currently logged in


This page shows the latest Galapagos news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema,

Daily brief: Novartis spends big on ezcema,

Novartis eczema deal worth up to $1bn for biotechs. MorphoSys and Galapagos have signed a major new deal with Novartis on their atopic dermatitis candidate MOR106, an IL-17c antibody.

Latest news

More from news
Approximately 4 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    271. Galapagos/ AbbVie. Agreement extension. Cystic fibrosis alliance for development of a triple combination therapy; increase in milestones from $350m to $600m.

  • Deal Watch December 2015 Deal Watch December 2015

    therapy areas such as oncology and, this month inflammatory disease, following the licensing deal with Galapagos for over $2bn. ... Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    195+. Galapagos/ Charles River. Acquisition of CRO business. Drug discovery services business.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Galapagos decided to sell its BioFocus and Argenta drug discovery service divisions to Charles River during the month so that it could focus on being an R&D company and use

  • Pharma deals during September 2013 Pharma deals during September 2013

    This is not AbbVie's only insurance policy against Humira's patent expiry; it already established an RA collaboration with another Belgian company, Galapagos, in February 2012. ... AbbVie paid an upfront fee of $45m with Galapagos eligible to receive a

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....